Cantuzumab mertansine
Cantuzumab mertansine is an antibody-drug conjugate investigated to treat colorectal cancer and other types of cancer. It is a humanized monoclonal antibody, cantuzumab linked to a cytotoxic agent, mertansine. It was developed by ImmunoGen.Mechanism
After the huC242 mab binds to the external domain of CanAg, the cantuzumab mertansine-CanAg complex is internalized, and the DM1 molecules are released intracellularly by cleavage of the DM1-huC242 disulfide bonds.Three phase I clinical studies had reported results by 2003. By 2005, clinical development had been suspended.
